Regulatory brokerage
Competitive advantage and regulation in the field of regenerative medicine
Bibliographic Data
| ID | 11923985 |
|---|---|
| Authors | Margaret Sleeboom-Faulkner (0000-0002-5342-8559, University of Sussex, corresponding author) |
| Year | 2019 |
| Volume | 49 |
| Issue | 3 |
| Pages | 355-380 |
| Publication date | 2019-06-01 |
| Peer Reviewed | Yes |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Social Studies of Science (JOURNAL) |
| Journal identifiers | ISSN: 0306-3127 • E-ISSN: 1460-3659 |
| Publisher | SAGE Publishing (PUBLISHER • US) |
| DOI | 10.1177/0306312719850628 |
| PMID | 31185876 |
| OpenAlex | W2951486448 |
| Language | EN |
| Citations received | 2 |
| References cited | 41 |
This article concerns the roles of entrepreneurial scientists in the co-production of life science research and regulation. Regulatory brokerage, defined as a mode of strategic planning and as the negotiation of regulation based on comparative advantage and competition, is expressed in scientific activities that take advantage of regulatory difference. This article is based on social science research in Japan, Thailand, India and the UK. Using five cases related to Japan's international activities in the field of regenerative medicine, I argue that, driven by competitive advantage, regulatory brokerage at lower levels of managerial organization and governance is emulated at higher levels. In addition, as regulatory brokerage affects the creation of regulation at national, bilateral and global levels, new regulation may be based on competition in regulatory advantage rather than on ethical and scientific values. I argue that regulatory brokerage as the basis for regulatory reform bypasses issues that need to be decided by a broader public. More space is needed for international and political debate about the socio-political consequences of the global diversity of regulation in the field of the life sciences
Biology · Business · Competition (biology · Competitive advantage · Corporate governance · Diversity (politics · Economics · Field (mathematics · Law and economics · Management · Market economy · Negotiation · Political science · Politics · Regenerative medicine · Regulatory competition · Regulatory reform · Regulatory science · Biomedical Ethics and Regulation · Biotechnology and Related Fields · Law · Science, Research, and Medicine · Marketing
Biocapital
Miti and the Japanese Miracle
Structures of Scientific Collaboration
Good Science
The Ethics of Clinical Research in the Third World
Introduction
When Experiments Travel
The Japanese Innovation System
State-Supported Science and Imaginary Lock-in
Experimental stem cell therapy
Stretching and Challenging the Boundaries of Law
Entrepreneurial scientists and entrepreneurial universities in American academic science
Introducing Regulatory Intermediaries
Hegemony in the marketplace of biomedical innovation
Comparing national home-keeping and the regulation of translational stem cell applications
Epistemic Cultures
When Do Scientists Become Entrepreneurs? The Social Structural Antecedents of Commercial Activity in the Academic Life Sciences
Bionetworking
Biotech Pilgrims and the Transnational Quest for Stem Cell Cures
| Unique citing works | 2 |
|---|---|
| Citations per year | 0,5 |
| Citation span | 2022 - 2023 (2) |
| Citation velocity | historical |
| Highly cited | No |
| Citation types | Neutral: 1 |